Plasma amyloid beta X-42/X-40 ratio and cognitive decline in suspected early and preclinical Alzheimer's disease.

ABSTRACT:

Introduction

Blood-based biomarkers are a cost-effective and minimally invasive method for diagnosing the early and preclinical stages of amyloid positivity (AP). Our study aims to investigate our novel immunoprecipitation-immunoassay (IP-IA) as a test for predicting cognitive decline.

Methods

We measured levels of amyloid beta (Aβ)X-40 and AβX-42 in immunoprecipitated eluates from the DELCODE cohort. Receiver-operating characteristic (ROC) curves, regression analyses, and Cox proportional hazard regression models were constructed to predict AP by Aβ42/40 classification in cerebrospinal fluid (CSF) and conversion to mild cognitive impairment (MCI) or dementia.

Results

We detected a significant correlation between AßX-42/X-40 in plasma and CSF (r = 0.473). Mixed-modeli

SUBMITTER: Vogelgsang J 

PROVIDER: S-EPMC11350048 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature